avns-20240104

0001606498-24-000002.txt : 20240104 0001606498-24-000002.hdr.sgml : 20240104 20240104080234 ACCESSION NUMBER: 0001606498-24-000002 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240104 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVANOS MEDICAL, INC. CENTRAL INDEX KEY: 0001606498 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 464987888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36440 FILM NUMBER: 24509795 BUSINESS ADDRESS: STREET 1: 5405 WINDWARD PARKWAY STREET 2: SUITE 100 SOUTH CITY: ALPHARETTA STATE: GA ZIP: 30004 BUSINESS PHONE: 844-428-2667 MAIL ADDRESS: STREET 1: 5405 WINDWARD PARKWAY STREET 2: SUITE 100 SOUTH CITY: ALPHARETTA STATE: GA ZIP: 30004 FORMER COMPANY: FORMER CONFORMED NAME: Avanos Medical, Inc. DATE OF NAME CHANGE: 20180702 FORMER COMPANY: FORMER CONFORMED NAME: Halyard Health, Inc. DATE OF NAME CHANGE: 20140424 8-K 1 avns-20240104.htm 8-K avns-20240104

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: January 4, 2024

(Date of earliest event reported)

AVANOS MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36440

46-4987888

(State or other jurisdiction of incorporation)

(Commission file number)

(I.R.S. Employer Identification No.)

5405 Windward Parkway

Suite 100 South

Alpharetta,

Georgia

30004

(Address of principal executive offices)

(Zip code)

Registrant’s telephone number, including area code: (844) 428-2667

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of exchange on which registered
Common Stock - $0.01 Par Value	AVNS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On January 4, 2024, Avanos Medical, Inc. (the “Company”) issued a press release that announced selected, unaudited preliminary financial results for the quarter and full-year ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1.

The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits

(d)Exhibits.


Exhibit No.						Description
99.1						Press release issued by Avanos Medical, Inc. on January 4, 2024
104						Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AVANOS MEDICAL, INC.

Date:

January 4, 2024

By:

/s/ Mojirade James

Mojirade James
Senior Vice President and General Counsel

EX-99.1 2 avns_01042024xex991.htm EX-99.1 Document


						Investor Contact: Michael Greiner
						Avanos Medical, Inc.
						470-562-2692
						Investor.Relations@Avanos.com

						Media Contact: Katrine Kubis
						Avanos Medical, Inc.
						CorporateCommunications@Avanos.com

Avanos Medical, Inc. Reports Preliminary Fourth Quarter and Full-Year 2023

Financial Results; Revises Preliminary 2024 Revenue Outlook

ALPHARETTA, Ga., January 4, 2024/PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported selected, unaudited preliminary financial results for the fourth quarter and full-year ended December 31, 2023 and revised its preliminary revenue outlook for 2024.

Preliminary Unaudited Financial Results

For the fourth quarter ended December 31, 2023, Avanos Medical, Inc. (the “Company”) expects net sales in the range of $170 million to $173 million, a decrease of approximately 6.5% to 4.5% compared to the same period in 2022, with net sales for the year ended December 31, 2023 anticipated to be in the range of $670 million to $673 million.

Net sales for the fourth quarter were lower than expected due to:

•Underperformance by the Company’s hyaluronic acid (“HA”) pain relief injection products, primarily as a result of continued pricing pressure due to the Medicare reimbursement changes. The Company estimates that net sales for the HA product line will be slightly above $10 million for the fourth quarter of 2023, which is approximately $4 million lower than anticipated.

•Lower than anticipated sales across the Company’s North America Digestive Health products, primarily due to a major distributor’s ordering pattern change.

•North America Pain Management and Recovery sales, while improved, were below internal expectations.

The Company anticipates that the lower than expected net sales will negatively impact adjusted gross margin, adjusted EBITDA margin and adjusted earnings per share for the fourth quarter and the full year. The Company is currently unable to quantify the overall impact on these measures.

“Although we are disappointed with our fourth quarter sales results, we were pleased with the execution of our three- year transformation initiative throughout 2023, which we believe positions us strongly for 2025,” stated Joe Woody, Avanos’ chief executive officer. “We are maintaining the 2025 financial objectives that we laid out at our Investor Day in June, and I look forward to updating investors on our overall progress next Monday at the JP Morgan Healthcare Conference.”

Revised Preliminary 2024 Revenue Outlook

The Company is updating its previous revenue guidance for the year ending December 31, 2024. For 2024, the Company now expects net sales in the range of $685 million to $705 million, reflecting continued HA market dynamics. The Company will provide additional information regarding its outlook for 2024 on the conference call it will host to discuss its financial results for the quarter and year ended December 31, 2023, which is currently scheduled for February 20, 2024.

The Company does not plan to release preliminary financial information on an ongoing basis. The financial information presented above is preliminary, is based on information available to management as of the date of this press release, and is subject to further changes upon completion of the Company’s standard quarter and year-end closing procedures. This update does not present all necessary information for an understanding of the Company’s financial condition as of the date of this press release or its results of operations for the quarter and year ended December 31, 2023. As the Company completes its quarter-end and year-end financial close processes and finalizes its financial statements for the quarter and year ended December 31, 2023, it will be required to make significant judgments in a number of areas. It is possible that the Company may identify items that require it to make adjustments to the preliminary financial information set forth above and those changes could be material. The Company does not intend to update such financial information prior to release of its financial statement information for the quarter and year ended December 31, 2023, which is currently scheduled for February 20, 2024.

About Avanos Medical, Inc.

Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today’s most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands globally and holds leading market positions in multiple categories across its portfolio. For more information, visit www.avanos.com and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.

Forward-Looking Statements

This press release contains information that includes or is based on “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “outlook,” “estimate,” “anticipate,” “plan” or “continue” and similar expressions. The forward-looking statements in this release include, without limitation, statements regarding the Company’s expectations regarding financial results for the fourth quarter and full-year ended December 31, 2023 and for the year ending December 31, 2024 and the impact of the Company’s transformation initiative. Forward-looking statements are based on the current plans and expectations of management and are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements as a result of a variety of factors. Such factors include, but are not limited to: completion of quarter and year-end closing procedures, weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; shortage in drugs used in our Surgical Pain and Recovery products or other disruptions in our supply chain; the ongoing regional conflicts between Russia and Ukraine and in the Middle East; our ability to successfully execute on or achieve the expected benefits of the Transformation Process or our divestiture, acquisition or merger transactions; inflationary pressures; the effects of the recent financial conditions affecting the banking system and the potential threats to the solvency of commercial banks; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the impact of investigative and legal proceedings and compliance risks; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; and changes in the competitive environment.

The information contained herein speaks only as of the date of this press release and we undertake no obligation to update forward-looking statements, except as may be required by the securities laws.

Additional information concerning these and other factors that may impact future results is contained in our filings with the U.S. Securities and Exchange Commission, including our most recent Form 10-Q.

EX-101.SCH 3 avns-20240104.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 avns-20240104_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 avns-20240104_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 avanoslogoa08a.jpg begin 644 avanoslogoa08a.jpg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end GRAPHIC 7 avns-20240104_g1.jpg begin 644 avns-20240104_g1.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_[@ .061O8F4 9 !_^$ AD5X:68 M $U- "H ( (!#@ " '0 ": 00!V &$ ;@!O ', 7P!L &\ 9P!O M %\ 8@!L &$ 8P!K #< 7P!2 $< 0@!? #0 , P ' > /_L !%$=6-K M>0 ! 0 !? #_X06&:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \ M/WAP86-K970@8F5G:6X](N^[OR(@:60](EG)E4WI.5&-Z M:V,Y9"(_/@T*/'@Z>&UP;65T82!X;6QN#IX;7!T:STB061O8F4@6$U0($-O7!E+U)E M&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA M<"\Q+C O(B!X;7!-33I/&UP34TZ1&5R:79E9$9R M;VT@&UP+FEI9#HS838S,38V9"TX-S!E+30Y M8S,M.#DT,BUD-V1D9&-A-F1F9&$B('-T4F5F.F1O8W5M96YT240](GAM<"YD M:60Z,V$V,S$V-F0M.#"UD M969A=6QT(CY!=F%N;W-?;&]G;U]B;&%C:S=?4D="7S0P,'!X/"]R9&8Z;&D^ M/"]R9&8Z06QT/@T*"0D)/"]D8SIT:71L93X\+W)D9CI$97-C"UD969A=6QT(CY!=F%N;W-?;&]G M;U]B;&%C:S=?4D="7S0P,'!X/"]R9&8Z;&D^/"]R9&8Z06QT/@T*"0D)/"]D M8SID97-C&UP;65T83X-"CP_>'!A8VME="!E;F0])W2SENC[!^RWUF]NJDU5=G!7 M'*=W#N5JJJK&YG9O ZRRJYP3LI44P.L83"!2$1*0A0$?FE* > :@_I M;[*NB^B;;L,]UOD1D+F0M@'E-G&XY2K^:J?(1N/5[U+IO/ZNY(JP'D6Z;=0Y M2"0)./([0,F7Q.J"/R>+L=&W#%Z424H=@U63AH - "&7>1Y5]Q3A;SPRGCVF M\M,W0.*[J6/ROBB-;682Q\74KEY@JQS2(0 M$P AV\M\.F901V*F=01\-&>KGRSM\U'@L!=6DH: #0!I1W%.433AQPSSOGT7 M*"$_5J57 M^6KV[8XS9WB7&1;P-%H?FL5'35,4TQ2/)RQW95!\0,1%(P>T=Z\):ED^L)PB M>#3A8: (\.ZERR/PPX-YLS+$R 1U[6A"T+%JP;^>3(MYZF3!='8I@ZXY,RS\ M.H.G^!'?PUC2W12;I7LROT#NV=RH/#_;/SE_RVG?_P +4/\ 2WV4]%]#%/IX M>YSG'.V;,L\;N3N7;/E*:M55;Y!Q1-760&0E&+^I&\F8BT%C&*4".&;A)T1( MI-]T5#;^(Z?AH[.&*UHDI0WCJH0&@ T &@"#CU >?#L-?\ !62;3BVY MK9NH\$M8ZB_^CI16&?,Y519L93I,/EJ'1(8P>_8-)W;JO S)2_(EQ']WGN6Q MT@PD4^9.:'"D>^:/TV[ZP$>L'"C-0JA4UT%$1373.)=E$S@)3%W*8! 1#4G] M;?91T7T/[=L3N"TCN(\;(7*425E"9-K LZOFJA(+=2E4NR:6_GH%$PJ"QEB$ M,X8J&^UZDQ$5$C[6YW[J2:]>C)&-,,!H TI[CM[N.,."7*S(6/K%)U&[4_"] MQGJQ9H9?X:5A)ABAU).$%-AZ#IF\0';6;^$S5/+17>?_ -;>Y5_;/SE^%/\ MY6H/Z6^RKHOH>9[%^:/?":2G,38HCVG M(/D/%F58RT!%2P-,=X[DB@("G.RJ(*'7'D9^S6"*&-XB)E5E#G$1_ M5'2YDU!F#%G*[DWA"1:2F(N0&8,>.62J:R256R%*1<IDSSCF2AZ=S1K+7.%",HV9NPUR+MBGP.:4V+J_F3!%[AL@4" MQIF!M*Q2HE:!P/OO[]]8-&Z. NY?SLXT2K.0Q1R;RFR8M%$! M&J6BR+7RD.44# 84CP\T+Y@0IP#I,9),I]O88!V$-UT=>&<=$_@QG> MX':G. \N8<>5W,\!4WMJ8KFH6(%%)9600<*J.J^NJLL0B1!5625, M.Q3ICTD&K+7OX9/IGU\C"^GB@T *%>J2Y9 PKN$N&-:DT_B)]T;-N4&S=4AU M$XR+,O'UQHMT'ZR LY%ZY.D=H+&;G3E:VZ2=I )R^(%.9+I-\H"(:ZG'DXU);&8 S) M6.0V$<4YQIJQ5JUE6AUJ[Q8!U=34D\U364;' Y2F [58QT5 $ $#%$->E5]E M)$U#@R]KIP- "O\ ZGOBP.0^-.,^4CG;LDR*ZZN#>+6S(: $T?5*\KOC)G!O M#2MR8"A#HK9NR@V;N"F*:3?E7C:XT6* =1#(-OCG)BF'8P*I&VW*&I?8M\%& M-?D4YQCCVRY;R-0\74UBM)6O(EOKM*KK%N@=PJXF+*[29H!T$ 3" **@)M@\ M W'4R4^!S<%LEQ[PS6N.^#<38,J")$:[BJ@UFDQXD,;&<1.0D M]Q3Y,X3Y#5P53/<67Z%L+UFB8"'EZV8PMI=AU" @4)"*7<-A';P ^^M5MU0UO5 =*E,X1*!A!(KMD(?$,5C?8*EV$?+.H!MYWZ. M3%Z]E!9UX>RYC_/6,*/F/%EA:VG'^1*^QLM7FV@_,=1[T/$BA/LD5FZ@&171 M-\Y-0IB& #%$->@GV4HD:@R3KIPC][K'Z.#FA^0"^?$A\E6 M$8[CSA&923>1%WR!&KN[/;HY4-R.(2OIF0<.4% V$CETL@D8!ZDC*AOIU,7< M5;55)[:QZ6+B)'QOE6S/V?[)+&1*4[Z+"!K3 B^WB=-L:-?*% 1\0*=1A[+-,VZJR-$S7"HQ!I=0@@()H3T27R43F+N! M068 41VZE"!N(9MZWTS2V^Q5_.>!,P\:6NW3G%A?*DY? M6'%EE=Q\?F3%"CT4HB[5I(X@*Z!3;I-I)@0YSLG6VX#NF?J2.)1U>GV4HD:@R3KIPPOR-S#&\?,!YESC+I%<,,3XTN5]5:G*8Y'BE98+ND MD! ABF$%E4RD'I$!\?#7+/JI.I2X*G?*63+IF;(]WROD6:=6&\Y#LTO;;1,N MU3JJO9>:6,LJ(=9CF*0@FZ$B;[%(!2AX &O-;GR6I02.=L#M09@[EEMLRE?L MD;C'#N/',-4FE22+]K-R=I\<;SG]'1@OZOYCC61A*7S&S%-9=G M.@GN(J V.FMM]@@<-Q!5\'7CR;KJGR,X=G[MQ07;VXT1T5/,H]YR!RHC&VS- MEE0 %E&C\R74RKK5;;?X6#35,0>GP47,LK]B8@%HRSZ+_HG2W9DL^FF#JOWS M2,8O)*0<)-&$>U MOP%1$P^'MUEGWDSI?K!"],1$E 2TI S3)>-F(21>Q$M'.B]#EA)1JID5T5 \ M=C)*D,4P?*&E#!Y7TPG*X,A<<,E<4[')D5LF!K*-NI#993_&7&,O:5!-M6'(T-J@2&@#"O(["=;Y(8&RY@BW)HF@ M/>>4Y3\?LB!KEEV4'4XR4C;5C^VV*E62/5+TJ,YVKNUF3M,0_Z"Z!@UYK4>"U.1L/TM?*T["RY MPX:V*45%I/,BYNQHT<+JJ(I2L4#>-L+9 H[I)BNV,R<=(;"/EJ&\=AU1Z]O@ M3M7Y'.=5DYYDU,1M>AY:?F7:,?#P<8_F)5^X.";=E&QB1UEUCF'P*5-(AC&' MY T 53'.CDM*\O>6F.O-O;LY+:KJH);O3:<6"YLYO2&;9Z-(\IO&"IJ6M$[EOYS57)- MP\Z.@4]QV IVZ)7KY,P>PZ!/ETWUZRY^C&MH4%@9JTE#0!\?D*]5O%]#NF2; MB^"-J=!JL_8<_6]0YIW*U^L%N60,H94D9'OUC Q8)"<1-Y4>Q(BV2 ?80A0]VO-L^S MDM2ZJ"4[MO\ :Y?Q^1N/)7\:B*C(&2\6WW#]F+ M4,C5N0K$\M!UZS,VC]/8DC6[8S1D(U^V4*(D70>LUR*I*$$0$!V]H" =:@XG M)/\ =@?NG_[*F4$.*F;IXZ7'G,=@2+4YV3=]+#$64)4Q4DW!C*#THQTV?I1> M>PJ:OEK_ #2^>)G8Z=?#X%:T[>4/V@(" " @(" " @.X" ZM)B/[NL?HX.:' MY +Y]S#K&G#-4Y15JZ\XM+%WTY_Z+?%?Y1,R?S^[U=A^237]$Y^G"S#/(K-% M?XZ8(R[G6T_.@L48^L]X>H>/4^- M5%D6Q>G!2%*4 M/ ->:W+DM2CP3Y^GW[8=3&?#9*RL5--V1! MXF8/+<,H1NHBX6*UOU$?L333133223(DDD0J:2 M290(FFF0-BE*4-@ -@ -6DQ^] !H C#[I_;AQWW#^/Q,W"KJ-G;98NX])T%TCD.&_@(#KS^"L< M:]+ER^D)6'S'PHM4F*Z-70-FG$B"ZG4HUB)%RDSLK%(.@.E--\X9NR )A^^KU[? C:OR-\ZJ$&D/;,[)%56RRL_'QT6ZA'C]4Q6[!P08Q!1F9,';ZR1&0TH5AD+D <,(TTJ3@$I!"/LR2AI]ZD4!!39O")KI H0=R M**I&^32MK=:C,ZRRMSU 5EEUV1.*0<4NWSB*+EXPL??LOMC9NR!UHE2>!(WM M)%2-;+"4Y^HS*$39HB&_@8#> #OJ_&O6I'I;LQ/_ +_O$\O&?N W:R0,9\!0 M.1<>GFBL^0B1)BWG9A4Z%A:D!)--,@IS"*KCRP\2D63$?:&\V]>MBC*THP-V M=>5JG$3GWA.]2$DHPHMWEPQ%DH@K*)LU*CD(Z30JZY2& #EC9'X5Z'5X *6^ MLY6ZV.Z5[(LZ]>@1AH - %?%ZD'BT&$.=(9C@X\&M.Y.51K=C*)%Z6Z60ZR" M<9.I 4J92$%9,C-X;YPB8ZQS#^K%O6'/V59.41,<(^1\OQ)Y7X+Y"11U13QU M?8E_86B0_.E*7)"9C.--A$"B+F)T0 M<+9J](-I> L43'3L'+,E/-9R AKTN2(A3]0+RK+ MQN[?=VJ4+)IL[]R0D$\,5U$BG2$6)1,R]E=D+X")"1"9F@F =RG<)B&D[VZ MU&95EE M4%D"NNT$E$_C$\8TT[=_-J 4Y#& CER9DS,8NP]*I@W]ND;VA0-RK+D0 006 MVCQ9:Y&N@?2,OYIB^"WPJZ_P9#C[4TB?)KTN*A>('/C.&-XF/+'46T37UK8T12(5-LC2)MD2D "D3C7WQ+$ MA?[E(-_;J+6O6Q5F^R-EO3[_:Z;<[^VOQ;RIBR%!3E)A/C%BM>FE:% KK)M)1@& M3AW5U_9YJP'ZEXLQA^:L)T@V*X.8++Y]ZI_)-6_5L1$=M'3!TY8OFSAD]9.% MFCQF[1,W=-'342O\ =8_1P*(7$/;.XG0\.@5)2WXV9Y5FUNG99Y.91 M54FE3J#L!C"FF\31+O["D*4/ #7H9**HCTL;1 21$DS_*!'R;=4 ^4@:,7% MD&BFI97ZO)#C52272507236063.DLBJ0%$E4E $#%,40$# 8!V$!T 5]'>;[ M-F1^(^1[IR#P14I*V\4;?+O;(X)7F:LD^P8_E53*KQTFB3S%21A%CC\$^'YA M2"5%8Q3@4RL6N3KY7!5GIV\/D7NT@:2+<2NZSSEX8J1[#$>:YV1HK$R91Q9D M,QKUCP[4G0 HH,GIS*QA1*0 W8*HF_5UNNCIPS%J*PUGP>]2IQTS<^AZ%RPJ MY>-5Z?BBS1OC5\I/X5E7R@](>>Y.7Z1KX',(;?%%51* "*CDH:II["?(FV37 M RK&2<;-1S"8AY!C+1,HS;2$9*1CM-_'2+!X0%$5T%TC'26353,!B'(80$! M0';5 D[V@"OX]25RO/FSFLQP/!2BKFD\8*V2MN6J2RGP*N3+@1"0FEN@1\LQ MV[8&30Q@#P,DU9&41 M0*TQQ2?Y2E^L_28J7Q3=O\(D8P;>8J0OM$-+SKV:1J]NJDM,V[=!H@BU:HHM MFS9%-NW;MTP10;H(@!2$(0H 4A2% #8 UZ)&+\^H[XH#GC@R.9(",%Y>. M+EB"^$40(47:V-[%Y+"QH[F,79- H-9!3;<>EL.WM'=&]>RGZ&Y6AE>_J(J+ M0#M%\K2\PN!6#\F2,@1_>:["?5;DW%C#/[QQLF6N7X46Z:BSU2JHE M^"L:!"I^ E+&K?&*=0; #??VZ3O7M49E:&5TNH2LL8O3ZH] MY5J9SYS&PS"22CBD<8*XE1RMDEE/@E<= F%,5$@,U9&,4/\ L!#Y M=(WM+@=E6$1*<*N.DMRSY58,X]Q*3@Y,I[,PO)IZ;H$# 5 MG%-W"QA ?#ITJE>S@W9]5):Z0,%$5>"A:U ,$(N!KL3'04)&-@$&T=$1")&[ M9!/J$1Z444RD+N/L#7I<$1ZV@ T 5MW?BY8&Y0]P;)3"%E!?X]P$0N#Z65!W M\1&KO*JLJ:>?(]!C(F^+G%7!"JD'YZ220^X-0;6[6*\ZPCYKL?\ %(W*ON#X MC8RT6K(4'#;D N1]V^I_8K*D=B_,".\+,25=F8FP0KQ>/F(*383$2_;*"DY8R48 MJ1=!9,Q1 Q3)*D*8H@/@(:C*"UEX*&;;H5:UR9RI(VM)$@;)MI9L+Y%IF5\9V*0J=^Q_88VT56P1BHI.HZ6BU .0?#P434 M !352. E4()B' 2F$!G3CR.:D?=LODF'4=1$IA\T6,H4IG#%0WM+U)B(J)*;6]^]6R;KTLBOEU"5%B[Z<_\ M1;XK_*)F3^?W>KL/R2:_HG/TX603>HUISJT=L/(,JT167-1,EXHMK@B*9E#% M9*2A8I4X@4!V*F$F!S"/@ (CX:3NO\ R,R?DKK-0E99_P#9WR3#Y1[:'$"; MAW)7)8#$D/CJ3 !W.A-XS.K NR'#V@/FL!-X^T! ?8(:]#)S5$>BALDMTPP& M@ T &@"N4]0]D>&R!W/,I,85?XDF-J3C;'$DH!1 A9F-CPD'*8#[#>4I)^6( MA[P$/: AJ'=S8JR4(Q!V.::]NO=(XHM&:)E"0-HM%R>J 03$;,JE 2KT3G'V M% 3I%( C]L8 ]^N8J;([I^6696KR0- '"X;H.T%VKI!%RUP8G;HEI+^ M15ZS>8^JZW3'& RA^H_P)VIS#]D<=)O@K?\ !E=7458YI]A;G'Q#CYBZ0]>C M^0^)XDJKIW=L1(+O9V'CDP,85Y2N*E&4:E(F03*J-@<(IAXF5 /'4U\;5'5U M5B$X0$!$!#80\! ? 0$-*&C/OI[>Z+<<3YCJ_"+,=F=S6%LKOAA<1/)R0\PV M+JC#2'#$ZTE2.<\GL[5KC'QZS% MGZVJIDA,54&?MAT%%01&4DV2(ECV!#" @"DC('0:I;_;G+JJUNJDG2EP5.U^ MN]CR9>KED:X/AD[9?;3/W*RR EZ/C9ZS.E7CM4"[CT@==8P@7?P#PUYS*(PU(S;S(L<6!'MS?DPQC-XX3(*@5JOG1?3[E P'$X$=R/PK<>HH?. M;&VU5Z]?D1M;X&X=4B#Y>[TZOY#IMKH-L8)2E7NM+?([,O'^SD5^DL77V>K*#M4ABA+0C=83 MQSX@G(F)B/H\Z*Y3 4 $#>'AKSK5ZN"VKE2,,>E]Y7#1L]Y5XEV*1.2 S77@ MOM$;K*"*#?(M!3-\8BF!C@4@R,()9 MJY"W&MV"HV6/;RU=M,)+5R?BG9/,:R<+.(*-73=4OVQ%D%3$,'R#HY#@J?N7 M_'Z9XK;: MO5P6U?922 ]F#N(17;\S5F"9'PC<6SF.22%7XO)-%:.9:K%\ -TB\ M=%7CBCML!G)1,(%*(ZWE?HS.E.Q$K=[C/Y$N=NO]K>C(VB\6:>M]DD!+T"^G MK(Z5>.UMO';S'"QS;>[?2VY-KP-7>EKXM%GO+$[/X'5]5DX: -).XQRC9\..& M6=L\&=)M[#7::]A\?I'4\L[S(]J_DZ$(7^#5W\M\X(LL*2;:TN!EC5 DPQR*PI5^1V"_<$UI'L?D;CR5_&HBHME^&7^Z'Q=_-\P]_H_'Z]*G"(;JQ8:5<82.LE3MD+)URRU^7;%>1VQ9>W=R*=Q,,TE)/CWDY>2L6$K@Z 7)4F!% ,[KSU?;87L(*I"" M)O%5$R2H>)CE)Y^N?1_\*\[]D:*83Y&9/P&RRU#4*8\BN9PQ99L0Y,K;SJ7A MK)5+&D(%,HB!@*#A@OTKM%P^<0W4 #TG.4V:V=3;4F"=9.EB[Z<_]%OBO\HF M9/Y_=ZNP_))K^B<_3A9@+E/@R)Y,<<HG0>W/DL2@:O]+=Q0DY"\9KY MEV*+61@:]!CA3&CQPB02P0*DZO5TYN(/9FT4WG7-=))(FG6\([5402>': ?X@B"J MZ*B9%1)TB8IB@.X"&@#U] !H 0#]25Q/Q7Q[Y9X^R5BN&C*HWY%TV?MERJD, MV(RBT+S6GR;=[*(MT]B(?2R;M(ZI2% IE2**;=1S#J+>JJY15E:40 8ZM,K1 ML@T6ZP2RK:;I]RK%IAG"!A(LA*U]Z@[;G((>(&*LB40$/?I"<#.1TKU0_+ U M0PUB/B'6Y$R,QEJ<')N0DFZAB*%HE+.9&,:J]"@ )'\P<5NDY1\6H"&J_8M" M@GQK\B0FI"D<1X@>H7X2<2.,^&>.]7X[;G"..5LMY@E^:DETA]D.D:W5W*&YU=5# M-$>..;;+QNSUB+/%044+/XIOU-C@8-@' M=)8-_P!77I)R1-0?=:Z<#0 DGZH_BT:M9;PMRY@& %BLEP"V*;\NB4VR5OI@ M&U;Q>#B%P1P%B)\S*RMRE41OF0R=)RK? MU]R!M)OTE04*0X&9>>1IL(> ) > !KT8_+6X72O7HK$'RM]BVX,G;UN+!Z]1 M\IXV;MSF 3%'S.LVWSM3Z65W*'43JH9\#V^^3;[A]S%P-G]!9P2(IEX8-[JU M;J@D,ECZQ@:-G&X]7S!$T8Z6,GU ( <"F]I0T4MT_<$UI'L?D;CR5_&HBHME^&7^Z'Q=_-\P]_H_'Z]*G"(;BNH9JMNKDK .2''C*'%3-5]P-F&!5@;SC^:7BWQ-A/'S# ?GLY-@J M( #AI(MC$7;JA[2&#< ,!BAYUJ]7#+$^WDP?KATL7?3G_HM\5_E$S)_/[O5V M'Y)-?T3GZ<+#0 GKZB3M4S4W(2_< X_UL\DS^#6,'ZNGK>HK^5C4?DEZGSB;1X M-ZTXTX\R!G.YJME C)"SQQL:8^8N1$"E.Y4=>9,. * B;RDV9.K;I\PF^X8M M["7!I8M\B?/,?FYR&YV925RKR"N1YV0:HK,*I58I(T71Z%"K& PLH:.ZU"-B M'$I155.8ZJH@!E5#B "$M[N[ECZU5> X5<,LQ\Z\[UC!F'8@ZSR262?6^W.V MZAJUCJFHJ$*\F)18@"!$T"FV23 >M902I)@)S!HI1W<(+6ZJ2SWXM<;<<<1L M"XXX^8JCP9U''<$E&INU$2)2-AF5S&6D)5Z) V.YDWJBCA8?8 FZ2[% H!Z% M:]5"(V^SDV UHX1I]SON48Q[;V$2W2PMDK;EJ\%E8G"^,"JF1-:9Z/(F*SQ^ MJ3YS6-BQ72.[5 >HW45)/YYP$J]-/YHW2G=E>VS[BW,..Y92/-=CF6P-L_2T MFHYDI\@E/!O8%02@$ K%'ZF*D0FBF1%./,04RE*42@"A2G"+^CF?DJZ*(&KN M*7J@\!VR$C87EYC&U8FN:#4JS2"[ZHSAW4[_FOF7SGSCF&/Q?E)]26M@-C[&!BT*4.W#'E"$[!BLB(,B#T2 M*A%G^Q@W 5A ?'7=6[6;.475$>'U'YJ_%!E'\ );[TUB#G.SK>+OPODL!Y/KUN@+=QMM2D%!&MD$[AE M)/&=T%>1B@0,[(F9?Z/=E>MC%*&R:94 ^V#5N%I4$VJ\C!6G"@T 1N=VSBN/ M+_@3G;%T9'#)7>$KXY.QFBDF99V>^8\ []LW;E*("962:E<,"[^'\/XZ7K7M M5HW1]65HWU'YI'Q#$&4!_P#H$M]Z:@AEQ^1N7(A M:.$,T@ B.("+NO8\M\HLO*V' 4\J$1CZ:?JB8ZJM<>E*8D&HL8=P9+%^&W$> MA1N0 (,VF$^:CJ:QX8H?GGBGR0XP3RUK)\&O^N&CTX:%F;%)LX2OQ,G.S,BL5O'Q$ M,P5DY-\X/[$T6Z!#JJF'W%*41T'"<#A#V ^:W*F2A[#D^N.N,6'EU&KE]:LF M1AT+U*1IS%%0L36#'2D#*BF/S3O_ (=+W@8PATZ=3!VY\"[:JH\MPKX,8$C^]9$G4"B4'DN^!-,5/+ Q@0;IE*BB B"1"]1A- M92BHO!/:SMR;AZT9#0!K7RHXCX#YG8LD\0\@J*QN-8>>8XBGY1^!M%0F>@Q$ MY&&D2%%=@Y1W\#%W*<-R*D.F)B#FU%?PSM;.O D!SG].QRUXYR$W;>.C9UR@ MQ B*[QJG76I&V8(!@7K/Y3Z"*(?29DB% /.C1.)Q\?(2WZ=27P=>/)375/D@ M$LU5L]+FGM;N-6W-BRLH+ 6(+'/PZS@$I/(LRT4KN,*ZB4W2HH]G')"L]TPW'R$146 M-L($2./AK=:._!FUE7DL#NUOVM\6]MK%KZ.CGS:^YQOS:/4ROE51A\+\:+,. MM.(ATS[JM(UFJ8QBE,/6L?\ A5=A!--*W/-9HEO?N29I_P 6G^T+^QIA@_>@ M T &@ T &@ T T &@# MA#K-N#M>2M4Y0?ZY)K_+UO\,74%N2Q<#8785_^ M->?Y(T_?AJC 1H-":I$AH - !H - !H 7;[ZO^KIO_DC_P#>IZ1J,S%!.)'^ E\# _Y\;?X74M.2E\%F'@G_5/2?\ ,;#_ 1->@B-\F7-=.'_V0$! end XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover Page Cover Page	Jan. 04, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	Jan. 04, 2024
Entity File Number	001-36440
Entity Registrant Name	AVANOS MEDICAL, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4987888
Entity Address, Address Line One	5405 Windward Parkway
Entity Address, Address Line Two	Suite 100 South
Entity Address, City or Town	Alpharetta,
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30004
City Area Code	844
Local Phone Number	428-2667
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock - $0.01 Par Value
Trading Symbol	AVNS
Security Exchange Name	NYSE
Entity Emerging Growth Company	false
Entity Central Index Key	0001606498
Amendment Flag	false

XML 9 avns-20240104_htm.xml IDEA: XBRL DOCUMENT 0001606498 2024-01-04 2024-01-04 0001606498 false 2024-01-04 8-K 2024-01-04 AVANOS MEDICAL, INC. DE 001-36440 46-4987888 5405 Windward Parkway Suite 100 South Alpharetta, GA 30004 844 428-2667 false false false false Common Stock - $0.01 Par Value AVNS NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Cover Page Sheet http://www.avanos.com/role/CoverPageCoverPage Cover Page Cover Page Cover 1 false false All Reports Book All Reports avns-20240104.htm avns-20240104.xsd avns-20240104_lab.xml avns-20240104_pre.xml avns-20240104_g1.jpg http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "avns-20240104.htm": { "nsprefix": "avns", "nsuri": "http://www.avanos.com/20240104", "dts": { "inline": { "local": [ "avns-20240104.htm" ] }, "schema": { "local": [ "avns-20240104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "avns-20240104_lab.xml" ] }, "presentationLink": { "local": [ "avns-20240104_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.avanos.com/role/CoverPageCoverPage", "longName": "0000001 - Document - Cover Page Cover Page", "shortName": "Cover Page Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "avns-20240104.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "avns-20240104.htm", "first": true, "unique": true } } }, "tag": { "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001606498-24-000002-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001606498-24-000002-xbrl.zip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end